Other
11 Authors
- Hou M,
- Ni H,
- Freedman J,
- Kim M,
- Aslam R,
- Guo L,
- McKenzie CG,
- Semple JW,
- Lazarus AH,
- Speck ER,
- Yang L
| First Author | Guo L | Year | 2014 |
| Journal | Blood | Volume | 123 |
| Issue | 3 | Pages | 422-7 |
| PubMed ID | 24258817 | Mgi Jnum | J:208083 |
| Mgi Id | MGI:5560872 | Doi | 10.1182/blood-2013-08-523308 |
| Citation | Guo L, et al. (2014) Allogeneic platelet transfusions prevent murine T-cell-mediated immune thrombocytopenia. Blood 123(3):422-7 |
| abstractText | Platelet transfusions are life-saving treatments for many patients with thrombocytopenia; however, their use is generally discouraged in the autoimmune disorder known as immune thrombocytopenia (ITP). We examined whether allogeneic platelet major histocompatibility complex (MHC) class I transfusions affected antiplatelet CD61-induced ITP. BALB/c CD61 knockout mice (CD61(-)/H-2(d)) were immunized against platelets from wild-type syngeneic BALB/c (CD61(+)/H-2(d)), allogeneic C57BL/6 (CD61(+)/H-2(b)), or C57BL/6 CD61 KO (CD61(-)/H-2(b)) mice, and their splenocytes were transferred into severe combined immunodeficient (SCID) mice to induce ITP. When nondepleted splenocytes were transferred to induce antibody-mediated ITP, both CD61(+) platelet immunizations generated immunity that caused thrombocytopenia independently of allogeneic MHC molecules. In contrast, when B-cell-depleted splenocytes were transferred to induce T-cell-mediated ITP, transfer of allogeneic MHC-immunized splenocytes completely prevented CD61-induced ITP development. In addition, allogeneic platelet transfusions into SCID mice with established CD61-induced ITP rescued the thrombocytopenia. Compared with thrombocytopenic mice, bone marrow histology in the rescued mice showed normalized megakaryocyte morphology, and in vitro CD61-specific T-cell cytotoxicity was significantly suppressed. These results indicate that antibody-mediated ITP is resistant to allogeneic platelet transfusions, while the T-cell-mediated form of the disease is susceptible, suggesting that transfusion therapy may be beneficial in antibody-negative ITP. |
